Adolor Corp (ADLR)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

700 PENNSYLVANIA DRIVE EXTON, PA 19341

Operates as a development-stage biopharmaceutical company specializing in the discovery, development and commercialization of prescription pain management products. Its lead product candidate, Entereg, is designed to selectively block the unwanted effects of opioid analgesics on the GI tract.

View SEC Filings from ADLR instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ADLR (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ADLR BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BAKER BROTHERS LIFE SCIENCES CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
No longer subject to file 2011-12-19 0

BAKER / TISCH CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
No longer subject to file 2011-12-19 0

14159 CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
No longer subject to file 2011-12-19 0

BAKER BIOTECH CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
No longer subject to file 2011-12-19 0

WEBSTER STEPHEN W SVP, FINANCE & CFO

  • Officer
No longer subject to file 2011-12-12 0

LIMONGELLI JOHN M SVP, GENERAL COUNSEL & SECR.

  • Officer
No longer subject to file 2011-12-12 0

NICKELSON DONALD E

  • Director
No longer subject to file 2011-12-12 0

CUBIST PHARMACEUTICALS INC

FRD ACQUISITION CORP

  • 10% Owner
88,378,182 2011-12-09 0

DOUGHERTY MICHAEL R PRESIDENT & CEO

  • Officer
  • Director
0 2011-12-07 0

MAURER GEORGE R SVP, MFG. & PHARM TECHNOLOGIES

  • Officer
0 2011-12-07 0

GEMAYEL GEORGES

  • Director
0 2011-12-07 0

ANIDO ARMANDO

  • Director
0 2011-12-07 0

NASH CLAUDE

  • Director
0 2011-12-07 0

GODDARD PAUL

  • Director
0 2011-12-07 0

HAGER GEORGE V JR

  • Director
0 2011-12-07 0

MAGNI GUIDO

  • Director
0 2011-12-07 0

MADDEN DAVID

  • Director
0 2011-12-06 0

BAKER BROS. CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
0 2011-06-30 0

SALINAS ELISEO ORESTE SVP R&D & CMO

  • Officer
88,675 2010-05-24 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

BVF INC/IL

LAMPERT MARK N

  • 10% Owner
  • DIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNER
No longer subject to file 2009-09-22 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

BVF INC/IL

  • 10% Owner
  • INDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNER
6,214,551 2008-10-31 0

MANNING MARTHA E SR.VP, GENERAL COUNSEL & SEC.

  • Officer
11,465 2008-05-20 0

JACKSON DAVID SR. VP AND CMO

  • Officer
7,355 2008-05-20 0

HESS THOMAS P VP FINANCE & CFO

  • Officer
6,247 2008-05-20 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments